Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Financials
Pharma
Bayer sells cancer drug Stivarga to Grünenthal for up to $431M
Patent protection for Stivarga is expected to last until 2029 in the EU and 2030 in the U.S., but has already expired in China.
Angus Liu
Sep 21, 2026 10:20am
Trump’s Medicare GLP-1 update teases blockbuster sales for Lilly
Sep 2, 2026 10:30am
Ascendis pays 20% royalties in patent settlement with BioMarin
Aug 31, 2026 1:56pm
BridgeBio’s Attruby cruises toward blockbuster land
Aug 11, 2026 11:22am
Sarepta's new CEO faces critical tests to prove growth
Aug 6, 2026 11:15am
Narcan maker Emergent axes top R&D post in sweeping restructuring
Aug 5, 2026 8:16pm
